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A multicentre. long-term. open-label, add-on study of vigabatrin was undertaken in 23 pretreated children with infantile spasms. 
After 3 months of vigabatrin therapy I I of the 23 patients had become seizure-free. At this time two-thirds of these I1 children 
still received other antiepileptic drugs (AEDs) in addition to vigabatrin (mostly valproic acid and/or dexamethasone). After a 
mean follow-up time of 5 $ years (range: 4+-6;) 72% of I8 evaluable patients (two children died, three were lost to follow-up) 
revealed seizure freedom for at least I year. The mean duration of vigabatrin therapy had been 24 years (range: 2 weeks to 
4$ years). Two-thirds of the I8 children continued to take AEDs. three of them undergoing vigabatrin monotherapy. Relapses 
of infantile spasms had occurred in 14% of the children. The rate of vigabatrin side effects (10%) was low. At follow-up, the 
EEG of I3 and the I8 patients demonstrated focal or multifocal epileptic discharges. Fifty-five percent had developed another 
epilepsy (focal epilepsy, secondary generalized epilepsy or myoclonic-astatic epilepsy). With respect to mental functions, three 
children were normal or slightly retarded, four showed moderate retardation and I I revealed severe or very severe retardation. 
This long-term result is comparable to that in ACTH studies with unselected patients. The conclusions are: (I) vigabatrin is an 
effective drug for the short-term and long-term treatment of refractory infantile spasms; (2) the relapse rate is low; (3) vigabatrin 
is well tolerated; (4) with respect to secondary epilepsies and mental functions the long-term outcome in these pretreated children 
is similar to that in earlier studies with ACTH or corticosteroids. 
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INTRODUCTION 
West syndrome is an age-related generalized epilepsy 
which usually manifests before the end of the first 
year of life. This condition is characterized by the 
triad of infantile spasms as a peculiar type of seizure, 
the characteristic EEG pattern of hypsarrhythmia 
and psychomotor retardation or deterioration. 
Symptomatic West syndrome is associated with 
multiple aetiological factors. In the idiopathic/ 
cryptogenic cases there is no known underlying cause. 
The pathogenesis of this condition remains largely 
unknown. 
Since 1958 ACTH and corticosteroids have been 
reported to be effective drugs for treatment of 
infantile spasms’. This hormone therapy has been 
the standard treatment of many years. According to 
numerous therapeutic trials, about X1-80% of cases 
have shown cessation of seizures and disappearance 
of the hypsarrhythmic EEG pattern’. However, this 
therapy is associated with frequent side effects, some 
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of which are potentially fatal (e.g. infections and car- 
diomyopathy). A high relapse rate after discontinuation 
has been reported, which may range from 30-65%*. 
The severe long-term prognosis for West syndrome was 
not improved by the hormonal therapy*. 
There is an increasing body of evidence that vigaba- 
trin is a very effective drug in this catastrophic epilepsy. 
In the first studies it was used as add-on therapy, and 28- 
7 1% of refractory cases became seizure-free3-6. More 
recent publications have indicated that vigabatrin as a 
primary drug seems to be at least as effective as ACTH, 
the percentage of seizure-free patients ranging between 
43% and 68%‘-“. In one trial comparing vigabatrin 
and hydrocortisone in infantile spasms due to tuberous 
sclerosis (11 patients each group) all vigabatrin patients 
became seizure-free’*. 
The objective of the present study was to evaluate 
the long-term efficacy and safety of vigabatrin as add- 
on therapy in pretreated children with infantile spasms, 
and to compare the outcome with that from ACTH or 
corticosteroids as the standard therapy. 
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Table 1: Patient characteristics. 
Gender: male 12, female I I 
Age at manifestation of 
infantile spasms (IS), mean (range): 6 months (2-13) 
Aetiology 
Cryptogen 4/23 (17%) 
Symptomatic 19/23 (83%) 
Hypoxic-ischemic encephalopathy 7119 
Microcephalus and/or mental 
retardation prior to IS 3119 
Congenital hemiparesis 2119 
Post-immunization manifestation of IS 2/19 
Aicardi syndrome 2119 
Schizencephaly 1119 
lncontinentia pigmenti l/l9 
Walker-Warburg syndrome l/l9 
STUDY DESIGN AND PATIENTS 
The study was conducted as a prospective multicentre, 
long-term, open-label study. Inclusion criteria were a 
firmly established diagnosis according to the criteria 
of West syndrome and pretreatment with one or more 
antiepileptic drugs (AEDs), including corticosteroids 
or ACTH. 
Vigabatrin was added to these AEDs. The start- 
ing dose of vigabatrin was 50 mg/kg/day with 
50 mg/kg/day increments at 3-day to l-week intervals. 
Vigabatrin was titrated to response or to a maximal dose 
of 150 mg/kg/day. In the responders the concomitant 
AEDs should be withdrawn: vitamin B6 with a few 
days, clobazam or clonazepam within a few weeks, 
ACTH and dexamethasone within 3-6 months, and 
other AEDs according to general rules of antiepileptic 
therapy. In seizure-free patients withdrawal of vigaba- 
trin should be started after 2 years of treatment at the 
earliest. 
The protocol was designed in accordance with the 
Declaration of Helsinki. Informed consent from the 
parents or tutors was obtained in all cases. 
RESULTS 
Patient characteristics 
The trial was conducted on 23 children attending three 
paediatric clinics in Berlin from 1989 to 1997. Details 
of patients included in the study are presented in Ta- 
ble 1. 
Their mean age at commencement of vigabatrin ther- 
apy was 9; months (range: 2&22 months). 
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Table 2: Pretreatment of the 23 children with West syndrome. 
Patients Duration of 
Medication (N) pretreatment 
Valproate 6123 5 mo (2-8)” 
Valproate plus dexamethasone 4123b 
Valproate plus clobazam 2123 
; ~~;‘:f;y” 
Vitamin B6 5/23= I3 d (3-28)” 
Vitamin B,5 plus valproate 2/23d 4 wk: 8 wk 
Vitamin B6 plus clobazam l/23 4mo 
Vitamin Bg plus ACTH 1123 2 mo 
ACTH I I23 3 mo 
Clonazepam plus phenobarbitone l/23 l3mo 
N = number of Patients; d = days; wk = weeks; mo = months. 
a Mean (range). 
b Including two children with cryptogenic seizures. 
c.d Including one patient with cryptogenic seizures in each group. 
The following drugs had been used either alone or in 
combination prior to initiation of the vigabatrin ther- 
apy: valproic acid (14 patients), vitamin B6 (5 patients), 
dexamethasone (4 patients), clobazam (3 patients) and 
ACTH (2 patients). Table 2 gives more details of the 
pretreatment. 
Efficacy of short-term treatment 
After 3 months of vigabatrin treatment complete ces- 
sation of spasms was reported in about half the patients 
(11 of 23 children), the majority of the responders still 
receiving polytherapy (8 of the 11 patients), mostly 
vigabatrin plus valproic acid and/or dexamethasone 
(Table 3). All four children with cryptogenic infantile 
spasms became seizure-free. By administering a mean 
vigabatrin dose of about 100 mg/kg/day (range: 50- 
150 mg/kg/day), seizure freedom was achieved within 
1 week in six of the 11 patients, within 2 weeks in eight 
of these patients and within 5 weeks in all responding 
children. 
Results of long-term vigabatrin treatment 
An evaluation of the efficacy of vigabatrin after a mean 
follow-up time of 5: years (range: 44-64 years) is 
shown in Table 4. 
At the time of follow-up 13 of the 18 evaluable pa- 
tients (72%) had been seizure-free for at least 1 year. 
Three children were lost to follow-up, two children 
had died (1 patient with Walker-Warburg syndrome, 
1 patient with Aicardi syndrome). In six of the 13 
seizure-free patients antiepileptic medication was with- 
drawn after at least a 2-year seizure-free interval. The 
other seven seizure-free children, and the additional 
five children with an active epilepsy, continued to re- 
ceive antiepileptic drug treatment, as the time interval 
for attempting antiepileptic drug withdrawal was too 
short or because a secondary epilepsy had occurred. 
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Table 3: Response after 3 months of vigabatrin treatment. 
Vigabatrin therapy Patients (N) Seizure-free 
Monotherapy 8123 3/S (37.5%) 
Polytherapyb 15123 S/IS (53%) 
Total I l/23 (48%) 
N = number of patients. 
a More than 50% reduction of seizure frequency. 
b Co-medication: valproic acid, dexamethasone, carbamazepine. 
Responder ratea 
2/S (25%) 
5/l 5 (34%) 
7/23 (30%) 
No effect 
318 (37.5%) 
2/15 (12%) 
5/23 (22%) 
Table 4: Results of long-term treatment of pretreated infantile spasms with vigabatrin. 
Follow-up time (mean, range) 5: yr (4$f) 
Patients 
Lost to follow-up 3123 
Died 2123 
Evaluable patients IS/23 
Efficacy 
Seizure-free patients (at least I yr) 
AEDs withdrawn 
With AEDs 
Patients with AEDs 
AEDs other than vigabatrin (mono- or polytherapy) 
Vigabatrin therapy at follow-up 
Vigabatrin monotherapy 
Vigabatrin polytherapy 
Duration of vigabatrin therapy 
All patients (mean. range) 
Patients seizure-free by vigabatrin (mean, range) 
Maximum Vigabatrin dose (mean, range) 
Relapses of infantile spasms 
l3/18 (72%) 
6118 
7/18 
12/l 8 (66%) 
S/18 (44%) 
4/18 (22%) 
3/18 
l/l8 
2 ’ yr (2 wkli yr) 
5 
3;1 yr(l+$ yr) 
IO1 mg/kg/d (80-150) 
3/2l (14%) 
Tolerability 
Patients withdrawn due to severe adverse events 
Adverse events 
Irritability. hyperactivity 
o/2 I 
2/21 (10%) 
212 I 
EEG findings at follow-up 
Normal 
Abnormal 
Diffuse slowing 
Focallmultifocal epileptic discharges 
4/18 (22%) 
l4/18 (78%) 
l/l8 
l3/18 
Patients with subsequent epilepsies 
Focal and/or secondarily generalized seizures 
Myoclonic-astatic epilepsy 
I0118 (56%) 
S/l8 
2/18 
Mental functions 
Normal or slight retardation 
Moderate retardation 
Severe or very severe retardation 
AEDs = antiepileptic drugs; yr = years; wk = weeks. 
3/18 (17%) 
4/18 (22%) 
I l/l8 (61%) 
Table 5: Treatment of infantile spasms with vigabin in comparison with hormonal therapy: long-term outcome. 
Psychomotor development 
Mortality Normal or Moderate Severe Follow-up 
Patients rate slight retardation retardation retardation Epilepsy time” 
(W Treatment N (%) N (%) N (c/o) N (%) N (%) W Authors 
214 ACTH, dexamethasone 42/214( 19) 33/192( 17) 20/192( IO) 85/192(72) 136/192(71) 10.4 (3-19) Riikonenl” 
64 ACTH, prednisone 3/64(5) 6/64( IO) 14/64(21) 41/64(64) 34/64(53) 4(3/4-IO l/4) Glaze er 01~’ 
23 Vigabatrin 2/23(9) 3/18(17) 4/18(22) ll/l8(61) lO/l8(56) 5; (4a-6:) This study 
N = number of patients. 
a Mean range. 
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Four of these 12 children on medication received vi- 
gabatrin either in monotherapy (3 children) or poly- 
therapy (1 child). The other eight children were treated 
by standard antiepileptic drugs (mostly valproic acid 
and/or carbamazepine). 
The mean duration of vigabatrin therapy in all pa- 
tients was 24 years (range: 2 weeks-4: years). In the 
patients who became seizure-free with vigabatrin the 
mean duration of vigabatrin treatment was 3; years 
(range: li-4: years). The mean of the maximally ap- 
plied dose of vigabatrin during the whole observation 
time was 101 mg/kg/day (range: 80-l 50 mg/kg/day). 
There were three relapses of infantile spasms during 
the first 6 months of vigabatrin therapy. 
The rate of side effects of vigabatrin was low. Two 
children experienced hyperactivity and irritability dur- 
ing the first months of vigabatrin therapy, which re- 
solved after dose reduction. In no child had vigabatrin 
to be withdrawn because of side effects. 
At the time of follow-up only four of 18 children 
(22%) had a normal EEG, the great majority showed 
ongoing focal or multifocal epileptic discharges (13 of 
18 patients) and one patient revealed a diffuse slowing. 
Ten of the 18 patients (56%) developed subsequent 
epilepsies, eight patients had epilepsies with focal 
and/or secondarily generalized seizures and two pa- 
tients myoclonic-astatic epilepsy. One patient in whom 
a myoclonic-astatic epilepsy occurred after discontin- 
uation of vigabatrin was treated again with vigabatrin 
monotherapy and became seizure-free again. In a sec- 
ond patient a myoclonic-astatic epilepsy manifested 
during vigabatrin therapy. The change of the medi- 
cation to valproic acid plus ethosuximide resulted in 
seizure-freedom. 
With respect to mental functions, the majority of the 
patients (61%) were severely or very severely retarded, 
22% showed a moderate mental retardation and as 
many as 17% were within normal limits or only slightly 
retarded. Three of the four patients with cryptogenic in- 
fantile spasms were in the last group of patients, one 
child was moderately retarded. 
DISCUSSION 
Vigabatrin is a very promising alternative drug to 
ACTH or corticosteroids for treatment of children with 
infantile spasms. It has been shown to be very effective 
as add-on therapy and as a primary drug. In compari- 
son with hormonal therapy, vigabatrin has an excellent 
safety profile. 
The results after 3 months of vigabatrin add-on ther- 
apy in our prospective, open, uncontrolled three-centre 
trial in children with refractory infantile spasms are in 
accordance with the data from other reported trials3”, 
our results after short-term treatment have been pub- 
lished elsewhere6. All published studies document that 
vigabatrin seems to have considerably fewer and less 
severe side-effects than hormonal treatment. However, 
there are only a few data on the long-term effects of 
vigabatrin therapy on children with West syndrome. 
In spite of treatment with ACTH or corticosteroids 
the long-term prognosis for children with infantile 
spasms remained poor, as has been confirmed in virtu- 
ally all follow-up studies. These studies have reported 
a significant mortality rate of 5-20% and permanent 
mental retardation in about 80-90% of the patients. 
The probability of normal mental outcome for symp- 
tomatic seizures is very low (less than 15%), whereas it 
is much higher in those with cryptogenic spasms (about 
40%)‘. Unfavourable prognostic factors include poor 
initial response to treatment and persistent focal or mul- 
tifocal inter-ictal EEG abnormalities, and this was true 
of the patients of this study. 
Several methodological problems make it difficult to 
compare the long-term results of our study with those 
of hormonal therapy19. 
(1) Uncontrolled studies tend to exaggerate the pos- 
sible benefits of the investigated drug. Few well- 
controlled prospective single- or double-blind hor- 
monal studies have been performed, most studies 
have been retrospective. Our study is also an un- 
controlled study. 
(2) The number of patients that could be recruited for 
our study is rather small. In West syndrome there 
is a multiplicity of associated aetiological factors. 
Larger groups of patients are a prerequisite forcom- 
parable results, as all investigators agree that the 
most important predictor of treatment efficacy and 
long-term outcome is the underlying cause of the 
infantile spasms. 
(3) The patients in the present study had been pre- 
treated with various antiepileptic drugs and had 
turned out to be therapy-resistant against these 
drugs before vigabatrin was used. Because of this 
selection criterion the outcome is expected to be 
worse than in the studies with primary hormone 
treatment. 
To compare the long-term outcome of vigabatrin with 
the standard therapy of ACTH or corticosteroids, two 
more recently published hormone studies by Riikonen 
and colleagues 2o and Glaze and colleagues2’ were cho- 
sen, as they contain detailed information with respect 
to mortality, psychomotor development and secondary 
epilepsies. The data are presented in Table 5. 
In spite of the selection criterion of therapy resis- 
tance in our study the presented data demonstrate that 
the parameters of mortality rate, psychomotor develop- 
ment and occurrence of other epilepsies in this group of 
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patients are similar to those of the earlier hormone stud- 
ies. The selection criteria of theranv resistance in our 
1’A.C.T.H. Acra Neurologica Belgica 1958; 58: 130-141. 
2. Aicardi. J. Infantile spasms. In: Epileps)) in Children 
study may explain the high rate (72%) of children with 
focal or multifocal epileptic discharges after a mean 
observation time of nearly 5$ years. However, the rate 
of secondary epilepsies is not higher than in the cited 
studies. 
Three of the four patients from our study with crypto- 
genie West syndrome were mentally normal or only 
slightly retarded, and one of these children was moder- 
ately retarded. With vigabatrin all four patients became 
and remained seizure-free. This confirms the findings 
of all long-term studies that patients with cryptogenic 
infantile spasms have the better outcome. 
One of the major questions is how long vigabatrin 
should have been given to responders. According to 
the study design with seizure-free patients with with- 
drawal of vigabatrin should not be started until after 2 
years of treatment at the earliest. The mean duration of 
vigabatrin therapy in our patients who became seizure- 
free by this drug was 3: years (range: l&4: years), 
which would seem to be a long period of treatment. 
Several factors mav have contributed to this: the fact 
(Ed. J. Aicardi) 2nd Edition. Inremafional Review of Child 
Neurology Series. New York. Raven Press. 1994: pp. 18-43. 
3. Chiron, C.. Dulac. 0.. Beaumont, D. er al. Therapeutic trial 
of vigabatrin in refractory infantile spasms. Jortmal of Child 
Neurology 1991; 6 (Suppl. 2): 2852-2S59. 
4. Auerswald, G. Vigabatrin bei pharmakoresistenten Epilepsien 
im Kindesalter. Akruelle Neurofogie 1992; 19 (Sonderheft I): 
26-27. 
5. Buti, D., Lini. M., Rota, M. er a/. Vigabatrin (CVG) in in- 
fantile spasms (IS): results in I4 children. Epilepsia 1993; 34 
(Suppl. 2): 94. 
6. Siemes. H.. Brandl, U.. Spohr. H.-L. and Nell, S. Behandlung 
van BNS-Kriampfen mit Vigabatrin: Ergebnisse einer Add-on- 
Studie. Akruelle Neurologie 1995; 22: 97-103. 
7. Vles,J.S.H.,vanderHeyden.A.M.H.G.,Ghijs,A.andTroost,J. 
Vigabatrin in the treatment of infantile spasms. Neuropediarrics 
1993; 24: 230-23 I. 
8. Appleton. R.E., Nicolaides. P. and Montiel-Viesca. F. Viga- 
batrin monotherapy for infantile spasms. Epilepsia 1995; 36 
(Suppl. 4): 32. 
9. Buti, D.. Rota, M., Lini, M. er al. First-line monotherapy with 
vigabatrin in infantile spasms: longterm clinical and EEG evo- 
lution in 12 patients. Epilepsia 1995; 36 (Suppl. 3): S 102. 
10. Chiron. C., Dumas. C.. Dulac, 0. Ed al. Vigabatrin versus hy- 
drocortisone as first-line monotherapy in infantile spasms due 
to tuberous sclerosis. Epilepsia 1995; 36 (Suppl. 3): S265. . 
that these children had not responded to other drugs, the 
high percentage of children with ongoing focal epilep- 
tic discharges and the lack of experience with this drug 
when the study was started (in 1989). Consequently 
this study does not provide a definite answer. 
I I. Granstrom, M.L.. Gaily, E. and Lindahl, E. Vigabatrin as the 
first drug in infantile spasms. Epilepsia 1995; 36 (Suppl. 3): 
s102. 
12. Vigevano, F.. Cilio. M-R., Faberi. A. et al. Vigabatrin versus 
ACTH in the treatment of infantile spasms. Epilepsia 1995; 36 
(Suppl. 3): S265. 
13. Aicardi. J., Sabrily. IS Investigator and Peer Review Groups, 
Mumford. J.P. Dumas. C and-Wood. S. Vigabatrin as initial 
CONCLUSIONS 
therapy for infantile spasms: a European retrospective survey. 
Epilepsia 1996; 37: 638-642. 
In children with infantile spasms vigabatrin seems to be 
a very effective drug in both short-term and long-term 
treatment. After a mean follow-up time of 5; years, 
72% of 18 evaluable oatients were seizure-free. The 
14. Appleton, R.E. and Thornton, L. Double blind comparison of 
vigabatrin vs placebo in newly diagnosed and previously un- 
treated infantile spasms. Epilepsia 1996; 37 (Suppl. 5): 125. 
15. Humbertclaude, V.. Coubes, P.H., Rivier, E et al. Efficacy ofvi- 
gabatrin as first-line monotherapy in infantilespasms. Epifepsia 
1996; 37 (Suppl. 4): 67. . 
relapse rate of infantile spasms (14%) during vigaba- 
trin therapy was low. Vigabatrin was well tolerated: in 
no child did vigabatrin have to be withdrawn because 
of an adverse event. The only remarkable side effect 
was irritability and hyperactivity in about 10% of the 
children. In those children who had been resistant to 
other drugs before the administration of vigabatrin, the 
long-term outcome with respect to other epilepsies and 
mental functions was similar to the data reported for 
hormonal treatment. 
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